/Moderna%20Inc%20meds-by%20Ascannio%20via%20Shutterstock.jpg)
Cambridge, Massachusetts-based Moderna, Inc. (MRNA), a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases. The company is valued at $16.1 billion by market cap.
Companies worth $10 billion or more are generally described as “large-cap stocks,” and MRNA perfectly fits that description, with its market cap exceeding this mark, underscoring its size, influence, and dominance within the biotechnology industry. Moderna's ability to leverage its mRNA technology in the respiratory vaccine market gives the company a strategic advantage due to its quick development and potential for combination vaccines.